Officials at Novartis report that the company plans to expand its operations in North Carolina, creating a new flagship manufacturing hub with end-to-end manufacturing capabilities. The strategic investment is meant to ensure all key Novartis medicines for U.S. patients are manufactured in the U.S. and delivered to patients across the country at scale, according to Novartis.
The announcement is part of Novartis’ $23 billion investment in U.S.-based infrastructure over the next five years, designed to increase manufacturing capacity and enable 100% of the company’s key medicines to be produced end-to-end in the U.S.
As part of this flagship hub in North Carolina, Novartis will:
- Build a new site in Durham with the construction of two new facilities dedicated to manufacturing biologics and sterile packaging
- Build a new site in Morrisville with one facility to produce solid dosage tablets and…
Click here to view original postClick Here to Publish/Feature Your Company or Product News with Biotech Networks
